Pfizer Reports Positive Phase 2 Breast Cancer Results
New York, USA | March 17, 2026 Pfizer has announced positive topline results from its Phase 2 FOURLIGHT-1 clinical...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
New York, USA | March 17, 2026 Pfizer has announced positive topline results from its Phase 2 FOURLIGHT-1 clinical...
PALO ALTO, CA — December 5, 2025 — Guardant Health announced it will present 14 abstracts at the 2025...
Philadelphia, PA and Vancouver, BC — December 2, 2025 — BriaCell Therapeutics Corp. announced plans to present three major...
South San Francisco, Calif. – October 30, 2025 — BridgeBio Oncology Therapeutics, Inc. (BBOT) announced two poster presentations at...
BASEL, Switzerland, Sept. 26, 2025 — Novartis announced it will present 34 abstracts from its oncology pipeline at the...
Basel, Switzerland — September 22, 2025 — Positive phase III trial results from the evERA study reveal that the...
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C...
